Comments on: Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced NSCLC published in The Lancet Oncology

Comments on: Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced NSCLC published in The Lancet Oncology https://www.novumpr.nl/2016/04/13/head-to-head-study-demonstrating-giotrif-afatinib-significantly-improved-clinical-outcomes-compared-to-iressa-gefitinib-in-egfr-mutation-positive-advanced-nsclc-published-in-the-lancet/?utm_source=rss&utm_medium=rss&utm_campaign=head-to-head-study-demonstrating-giotrif-afatinib-significantly-improved-clinical-outcomes-compared-to-iressa-gefitinib-in-egfr-mutation-positive-advanced-nsclc-published-in-the-lancet NovumPR press releases Wed, 13 Apr 2016 11:22:15 +0000 hourly 1 https://wordpress.org/?v=6.8.3